MA39347B2 - Protéines de fusion d'uti - Google Patents

Protéines de fusion d'uti

Info

Publication number
MA39347B2
MA39347B2 MA39347A MA39347A MA39347B2 MA 39347 B2 MA39347 B2 MA 39347B2 MA 39347 A MA39347 A MA 39347A MA 39347 A MA39347 A MA 39347A MA 39347 B2 MA39347 B2 MA 39347B2
Authority
MA
Morocco
Prior art keywords
fusion proteins
uti fusion
uti
proteins
producing
Prior art date
Application number
MA39347A
Other languages
English (en)
Other versions
MA39347A1 (fr
Inventor
Aaron Chamberlain
Qiang Liu
Mathias Schmidt
Original Assignee
Takeda Pharmaceuticals Co
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Takeda Gmbh filed Critical Takeda Pharmaceuticals Co
Publication of MA39347A1 publication Critical patent/MA39347A1/fr
Publication of MA39347B2 publication Critical patent/MA39347B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des protéines de fusion d'uti, des séquences d'adn pour produire ces protéines, et des compositions pharmaceutiques et des méthodes d'utilisation correspondantes.
MA39347A 2014-02-24 2015-02-23 Protéines de fusion d'uti MA39347B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
PCT/US2015/017152 WO2015127391A1 (fr) 2014-02-24 2015-02-23 Protéines de fusion d'uti

Publications (2)

Publication Number Publication Date
MA39347A1 MA39347A1 (fr) 2018-06-29
MA39347B2 true MA39347B2 (fr) 2020-05-29

Family

ID=52629709

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39347A MA39347B2 (fr) 2014-02-24 2015-02-23 Protéines de fusion d'uti

Country Status (38)

Country Link
US (4) US9856310B2 (fr)
EP (2) EP3443978A1 (fr)
JP (4) JP6574431B2 (fr)
KR (3) KR102461210B1 (fr)
CN (2) CN110092837B (fr)
AR (1) AR101597A1 (fr)
AU (4) AU2015218704B2 (fr)
BR (1) BR112016019390B1 (fr)
CA (2) CA2939639C (fr)
CL (1) CL2016002136A1 (fr)
CR (1) CR20160444A (fr)
CY (1) CY1120997T1 (fr)
DK (1) DK3110434T3 (fr)
DO (1) DOP2016000202A (fr)
EA (2) EA202091567A1 (fr)
EC (1) ECSP16076535A (fr)
ES (1) ES2700149T3 (fr)
GE (1) GEP20196970B (fr)
HR (1) HRP20182029T1 (fr)
IL (1) IL247321B (fr)
JO (1) JO3729B1 (fr)
LT (1) LT3110434T (fr)
MA (1) MA39347B2 (fr)
MX (4) MX384070B (fr)
MY (1) MY178774A (fr)
NZ (3) NZ724196A (fr)
PE (1) PE20170257A1 (fr)
PH (1) PH12016501629B1 (fr)
PL (1) PL3110434T3 (fr)
PT (1) PT3110434T (fr)
RS (1) RS58285B1 (fr)
SG (2) SG10201708400QA (fr)
SI (1) SI3110434T1 (fr)
SM (1) SMT201800674T1 (fr)
TW (1) TWI694084B (fr)
UA (1) UA118866C2 (fr)
WO (1) WO2015127391A1 (fr)
ZA (1) ZA201606327B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700149T3 (es) * 2014-02-24 2019-02-14 Takeda Gmbh Proteínas de fusión de UTI
CA3066358A1 (fr) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. Agents d'activation destines a la transfection de cellules et/ou la production de vecteur raav ameliorees
WO2020106881A1 (fr) * 2018-11-20 2020-05-28 Diamedica Inc. Polypeptides d'ulinastatine modifiés
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
CN115515616A (zh) * 2020-03-05 2022-12-23 代阿麦迪卡美国股份有限公司 乌司他丁多肽

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DK0401508T3 (da) * 1989-05-13 1995-05-15 Bayer Ag Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
AU641568B2 (en) 1990-11-13 1993-09-23 Mochida Pharmaceutical Co., Ltd. Polypeptide,DNA fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
TR199801794T2 (xx) 1996-03-11 2000-07-21 Bayer Corporation �nsan bikunini.
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
AU2005229457B2 (en) * 2004-03-30 2010-11-25 Glaxo Group Limited Immunoglobulins
CA2578613A1 (fr) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Proteines de fusion a domaine de liaison
US8252905B2 (en) * 2005-06-03 2012-08-28 Mochida Pharmaceutical Co., Ltd. Anti-CD14 antibody fusion protein
HUE038243T2 (hu) 2005-12-29 2018-10-29 Dyax Corp Proteáz gátlás
PT2334705T (pt) * 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
US8329867B2 (en) * 2010-02-19 2012-12-11 Xencor, Inc. CTLA4-Ig immunoadhesins
KR20250037576A (ko) * 2011-04-29 2025-03-17 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료적 뉴클레아제 조성물 및 방법
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
WO2013082563A1 (fr) * 2011-12-01 2013-06-06 Protevobio, Inc. Inhibiteurs protéiques du complément et des voies du vegf, et procédés d'utilisation associés
CA2871468C (fr) * 2012-04-23 2021-09-21 Nrl Pharma, Inc. Proteine de fusion a base de lactoferrine et son procede de production
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
CN103044554B (zh) * 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
ES2700149T3 (es) * 2014-02-24 2019-02-14 Takeda Gmbh Proteínas de fusión de UTI

Also Published As

Publication number Publication date
BR112016019390A2 (pt) 2017-10-24
GEP20196970B (en) 2019-04-25
NZ760789A (en) 2023-03-31
CA3178241A1 (fr) 2015-08-27
MY178774A (en) 2020-10-20
KR102461210B1 (ko) 2022-10-31
AU2015218704B2 (en) 2019-05-02
JO3729B1 (ar) 2021-01-31
CN110092837B (zh) 2024-01-02
US9856310B2 (en) 2018-01-02
JP6938565B2 (ja) 2021-09-22
US20160362475A1 (en) 2016-12-15
CA2939639C (fr) 2023-01-24
HRP20182029T1 (hr) 2019-02-08
ZA201606327B (en) 2019-01-30
MX2024000004A (es) 2024-02-20
KR20220151005A (ko) 2022-11-11
EA202091567A1 (ru) 2021-07-30
EP3110434B1 (fr) 2018-09-19
MX384070B (es) 2025-03-14
NZ724196A (en) 2022-01-28
BR112016019390B1 (pt) 2023-11-14
EP3110434A1 (fr) 2017-01-04
PT3110434T (pt) 2018-12-19
JP2017512058A (ja) 2017-05-18
SG10201708400QA (en) 2017-11-29
ECSP16076535A (es) 2017-08-31
JP2019187427A (ja) 2019-10-31
TW201630931A (zh) 2016-09-01
PE20170257A1 (es) 2017-03-30
CN106232135B (zh) 2019-12-10
MA39347A1 (fr) 2018-06-29
CY1120997T1 (el) 2019-12-11
CN110092837A (zh) 2019-08-06
ES2700149T3 (es) 2019-02-14
IL247321A0 (en) 2016-09-29
JP6574431B2 (ja) 2019-09-11
CL2016002136A1 (es) 2017-08-11
EA201691702A1 (ru) 2017-01-30
CA2939639A1 (fr) 2015-08-27
DK3110434T3 (en) 2019-01-14
WO2015127391A1 (fr) 2015-08-27
KR20240155987A (ko) 2024-10-29
AU2021225156A1 (en) 2021-09-30
TWI694084B (zh) 2020-05-21
AU2021225156B2 (en) 2022-11-24
CR20160444A (es) 2017-04-21
AU2015218704A1 (en) 2016-09-22
AR101597A1 (es) 2016-12-28
AU2019204448A1 (en) 2019-07-11
IL247321B (en) 2020-06-30
PH12016501629A1 (en) 2017-02-06
NZ760008A (en) 2023-03-31
MX2019013124A (es) 2020-08-31
RS58285B1 (sr) 2019-03-29
DOP2016000202A (es) 2016-12-15
SMT201800674T1 (it) 2019-01-11
AU2019204448B2 (en) 2021-06-10
US20200040062A1 (en) 2020-02-06
JP2022002513A (ja) 2022-01-11
EP3443978A1 (fr) 2019-02-20
PH12016501629B1 (en) 2023-10-20
EA037256B1 (ru) 2021-02-26
AU2023200875A1 (en) 2023-04-27
CN106232135A (zh) 2016-12-14
US20220127334A1 (en) 2022-04-28
LT3110434T (lt) 2018-12-27
SI3110434T1 (sl) 2019-02-28
US10351618B2 (en) 2019-07-16
PL3110434T3 (pl) 2019-01-31
US20180072795A1 (en) 2018-03-15
UA118866C2 (uk) 2019-03-25
MX2016010950A (es) 2017-04-25
KR20160141718A (ko) 2016-12-09
SG11201606691QA (en) 2016-09-29
JP2023123763A (ja) 2023-09-05
KR102722304B1 (ko) 2024-10-28

Similar Documents

Publication Publication Date Title
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3679141C0 (fr) Méthodes et compositions pour inhiber l'expression de la ldha
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
EA202092435A3 (ru) Моноклональные антитела против bcma
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA40534B1 (fr) Inhibiteurs de mk2 et leurs utilisations
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MY193728A (en) Muscarinic receptor agonists
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MA39347B2 (fr) Protéines de fusion d'uti
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
MX377774B (es) Formulaciones de proteinas.
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2016138538A3 (fr) Utilisation thérapeutique d'anticorps de liaison à l'intégrine
MX2017008278A (es) Producto para el cuidado bucal y metodos para uso y fabricacion de este.
EA201691493A1 (ru) Замещенные n-арилпиридиноны
MA39230B1 (fr) Hexahydrofuropyrroles utilisés comme inhibiteurs de pde1
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
EA201692227A1 (ru) Производные сложных аминоэфиров
EP3387431A4 (fr) Systèmes, méthodes et compositions pour améliorer la spécificité de l'hybridation des acides nucléiques
AU2016250265A8 (en) (S)-2'-vinyl-abscisic acid derivatives
EA201691203A1 (ru) Твёрдые формы тенофовира
MA39355A1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants